Health Technology Assessment (Oct 2010)

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion-adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age

  • CS Waddington,
  • N Andrews,
  • K Hoschler,
  • WT Walker,
  • C Oeser,
  • A Reiner,
  • T John,
  • S Wilkins,
  • M Casey,
  • PE Eccleston,
  • RJ Allen,
  • I Okike,
  • S Ladhani,
  • E Sheasby,
  • P Waight,
  • AC Collinson,
  • PT Heath,
  • A Finn,
  • SN Faust,
  • MD Snape,
  • E Miller,
  • AJ Pollard

DOI
https://doi.org/10.3310/hta14460-01
Journal volume & issue
Vol. 14, no. 46

Abstract

Read online

Objective: To evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion-adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children aged 6 months to 12 years. Design: Multicentre, randomised, head-to-head, open-label trial. Setting: Five UK sites (Oxford, Bristol, Southampton, Exeter and London). Participants: Children aged 6 months to 38.0°C in those under 5 years of age (8.9% vs 22.4%). Conclusion: The adjuvanted vaccine, although reactogenic, was more immunogenic, especially in younger children, indicating the potential for improved immunogenicity of influenza vaccines in this age group. Trial registration number: ISRCTN89141709

Keywords